@article{abb5417160094323885c197fbab4752b,
title = "Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation",
abstract = "Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) and National Kidney Foundation to improve and standardize the care of patients with kidney disease who have indication(s) to receive ACR-designated group II or group III intravenous gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis (NSF) from group II GBCM in patients with advanced kidney disease is thought to be very low (zero events following 4931 administrations to patients with estimated glomerular filtration rate [eGFR] <30 mL/min per 1.73 m2; upper bounds of the 95% confidence intervals: 0.07% overall, 0.2% for stage 5D chronic kidney disease [CKD], 0.5% for stage 5 CKD and no dialysis). No unconfounded cases of NSF have been reported for the only available group III GBCM (gadoxetate disodium). Depending on the clinical indication, the potential harms of delaying or withholding group II or group III GBCM for an MRI in a patient with acute kidney injury or eGFR less than 30 mL/min per 1.73 m2 should be balanced against and may outweigh the risk of NSF. Dialysis initiation or alteration is likely unnecessary based on group II or group III GBCM administration.",
author = "Weinreb, {Jeffrey C.} and Rodby, {Roger A.} and Jerry Yee and Wang, {Carolyn L.} and Derek Fine and McDonald, {Robert J.} and Perazella, {Mark A.} and Dillman, {Jonathan R.} and Davenport, {Matthew S.}",
note = "Funding Information: Jeffrey C. Weinreb, MD, Roger A. Rodby, MD, Jerry Yee, MD, Carolyn L. Wang, MD, Derek Fine, MD, Robert J. McDonald, MD, PhD, Mark A. Perazella, MD, Jonathan R. Dillman, MD, MS, and Matthew S. Davenport, MD, Guarantors of integrity of entire study, JCW, CLW, DF, MSD; study concepts/study design or data acquisition or data analysis/interpretation, all authors; manuscript drafting or manuscript revision for important intellectual content, all authors; approval of final version of submitted manuscript, all authors; agrees to ensure any questions related to the work are appropriately resolved, all authors; literature research, JCW, RAR, JY, CLW, DF, MAP, JRD, MSD; clinical studies, JCW, RJM, MAP, MSD; statistical analysis, MAP; and manuscript editing, JCW, RAR, JY, CLW, DF, RJM, MAP, JRD, MSD. JCW: Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: is a consultant for Bracco and GE Healthcare; has grants/grants pending with Ascelia Pharma. Other relationships: is a medicolegal consultant for Bayer Healthcare. RAR disclosed no relevant relationships. JY disclosed no relevant relationships. CLW: Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: has grants/grants pending with GE Healthcare. Other relationships: disclosed no relevant relationships. DF disclosed no relevant relationships. RJM: Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: is a consultant for GE Healthcare; has grants/grants pending with Bayer and GE Healthcare. Other relationships: disclosed no relevant relationships. MAP disclosed no relevant relationships. JRD: Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: has grants/grants pending with Bracco Diagnostics and Guerbet. Other relationships: disclosed no relevant relationships. MSD: Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: receives royalties from Wolters Kluwer. Other relationships: disclosed no relevant relationships. This article is a simultaneous joint publication in Radiology and Kidney Medicine. The articles are identical except for stylistic changes in keeping with each journal's style. Either version may be used in citing this article. Received June 28, 2020; revision requested July 20, 2020; final revision received September 9, 2020; accepted September 11, 2020. Publisher Copyright: {\textcopyright} 2020 The Authors",
year = "2021",
month = jan,
day = "1",
doi = "10.1016/j.xkme.2020.10.001",
language = "English (US)",
volume = "3",
pages = "142--150",
journal = "Kidney Medicine",
issn = "2590-0595",
publisher = "Elsevier Inc.",
number = "1",
}